Inhibition of enveloped virus infection of cultured cells by valproic acid

Journal of Virology

Volumn 85, Issue 3, 2011, Pages 1267-1274

  Vázquez Calvo, Ángela ^a   Saiz, Juan Carlos ^b   Sobrino, Francisco ^a,c   Martín Acebes, Miguel A ^b  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^b INIA   (Spain)

^c Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

VALPROIC ACID; VIRUS RNA;

ANIMAL CELL; ANIMAL HEALTH; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL METABOLISM; DRUG METABOLISM; HUMAN; LIPID METABOLISM; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MATURATION; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; STOMATITIS; VESICULAR STOMATITIS; VESICULAR STOMATITIS VIRUS; VIRUS INFECTION; VIRUS INHIBITION; VIRUS MENINGITIS; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; HUMANS; VALPROIC ACID; VIRUS INTERNALIZATION; VIRUS REPLICATION; VIRUSES;

ANIMALIA; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; VESICULAR STOMATITIS VIRUS; WEST NILE VIRUS;

EID: 78651399814     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01717-10     Document Type: Article

References (61)

1. Albertini, A. A., G. Schoehn, W. Weissenhorn, and R. W. Ruigrok. 2008. Structural aspects of rabies virus replication. Cell Mol. Life Sci. 65:282-294.
2. Armas-Portela, R., M. A. Parrales, J. P. Albar, A. C. Martinez, and J. Avila. 1999. Distribution and characteristics of betaII tubulin-enriched microtubules in interphase cells. Exp. Cell Res. 248:372-380.
3. Asenjo, A., J. C. Gonzalez-Armas, and N. Villanueva. 2008. Phosphorylation of human respiratory syncytial virus P protein at serine 54 regulates viral uncoating. Virology 380:26-33.
4. Blasco, R., and B. Moss. 1992. Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J. Virol. 66:4170-4179.
5. Brinton, M. A. 2002. The molecular biology of West Nile Virus: a new invader of the western hemisphere. Annu. Rev. Microbiol. 56:371-402.
6. Bruni, J., and B. J. Wilder. 1979. Valproic acid. Review of a new antiepileptic drug. Arch. Neurol. 36:393-398.
7. Buckley, A., et al. 2003. Serological evidence of West Nile virus, Usutu virus and Sindbis virus infection of birds in the UK. J. Gen. Virol. 84:2807-2817.
8. Codd, R., N. Braich, J. Liu, C. Z. Soe, and A. A. Pakchung. 2009. Zn(II)- dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A. Int. J. Biochem. Cell Biol. 41:736-739.
9. Colman, P. M. 2009. New antivirals and drug resistance. Annu. Rev. Biochem. 78:95-118.
10. Cordoba, L., E. Escribano-Romero, A. Garmendia, and J. C. Saiz. 2007. Pregnancy increases the risk of mortality in West Nile virus-infected mice. J. Gen. Virol. 88:476-480.
11. Countryman, J. K., L. Gradoville, and G. Miller. 2008. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors. J. Virol. 82:4706-4719.
12. Cramer, J. A., R. H. Mattson, D. M. Bennett, and C. T. Swick. 1986. Variable free and total valproic acid concentrations in sole- and multi-drug therapy. Ther. Drug Monit. 8:411-415.
13. de Silva, A. M., W. E. Balch, and A. Helenius. 1990. Quality control in the endoplasmic reticulum: folding and misfolding of vesicular stomatitis virus G protein in cells and in vitro. J. Cell Biol. 111:857-866.
14. Domingo, E., and J. Gomez. 2007. Quasispecies and its impact on viral hepatitis. Virus Res. 127:131-150.
15. Enjuanes, L., A. L. Carrascosa, M. A. Moreno, and E. Vinuela. 1976. Titration of African swine fever (ASF) virus. J. Gen. Virol. 32:471-477.
16. Garcia-Briones, M. M., et al. 2004. Immunogenicity and T cell recognition in swine of foot-and-mouth disease virus polymerase 3D. Virology 322:264-275.
17. Gastaminza, P., C. Whitten-Bauer, and F. V. Chisari. 2010. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proc. Natl. Acad. Sci. U. S. A. 107:291-296.
18. Gilbert, C., M. Bergeron, S. Methot, J. F. Giguere, and M. J. Tremblay. 2005. Statins could be used to control replication of some viruses, including HIV-1. Viral Immunol. 18:474-489.
19. Gillespie, L. K., A. Hoenen, G. Morgan, and J. M. Mackenzie. 2010. The endoplasmic reticulum provides the membrane platform for biogenesis of the flavivirus replication complex. J. Virol. 84:10438-10447.
20. Gower, T. L., and B. S. Graham. 2001. Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob. Agents Chemother. 45:1231-1237.
21. Hackett, A. J., F. L. Schaffer, and S. H. Madin. 1967. The separation of infectious and autointerfering particles in vesicular stomatitis virus preparations. Virology 31:114-119.
22. Hsu, N. Y., et al. 2010. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 141:799-811.
23. Jimenez-Clavero, M. A., et al. 2005. Survey of bovine enterovirus in biological and environmental samples by a highly sensitive real-time reverse transcription- PCR. Appl. Environ. Microbiol. 71:3536-3543.
24. Kalvodova, L., et al. 2009. The lipidomes of vesicular stomatitis virus, Semliki forest virus, and the host plasma membrane analyzed by quantitative shotgun mass spectrometry. J. Virol. 83:7996-8003.
25. Kanner, A. M. 2003. The pharmacology of parenteral valproate. Epilepsy Curr. 3:109-111.
26. Khattab, M. A. 2009. Targeting host factors: a novel rationale for the management of hepatitis C virus. World J. Gastroenterol. 15:3472-3479.
27. Lanciotti, R. S., et al. 2000. Rapid detection of West Nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a Taq-Man reverse transcriptase-PCR assay. J. Clin. Microbiol. 38:4066-4071.
28. Le Blanc, I., et al. 2005. Endosome-to-cytosol transport of viral nucleocapsids. Nat. Cell Biol. 7:653-664.
29. Lehrman, G., et al. 2005. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366:549-555.
30. Letchworth, G. J., L. L. Rodriguez, and J. Del Cbarrera. 1999. Vesicular stomatitis. Vet. J. 157:239-260.
31. Lezin, A., et al. 2007. Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients. Blood 110:3722-3728.
32. Li, F., G. F. Browning, M. J. Studdert, and B. S. Crabb. 1996. Equine rhinovirus 1 is more closely related to foot-and-mouth disease virus than to other picornaviruses. Proc. Natl. Acad. Sci. U. S. A. 93:990-995.
33. Lichty, B. D., A. T. Power, D. F. Stojdl, and J. C. Bell. 2004. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol. Med. 10:210-216.
34. Luan, P., L. Yang, and M. Glaser. 1995. Formation of membrane domains created during the budding of vesicular stomatitis virus. A model for selective lipid and protein sorting in biological membranes. Biochemistry 34:9874-9883.
35. Ludwig, S. 2009. Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J. Antimicrob. Chemother. 64:1-4.
36. Mackenzie, J. M., and E. G. Westaway. 2001. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J. Virol. 75:10787-10799.
37. Martin, V., A. Grande-Perez, and E. Domingo. 2008. No evidence of selection for mutational robustness during lethal mutagenesis of lymphocytic choriomeningitis virus. Virology 378:185-192.
38. Martin-Acebes, M. A., et al. 2008. Subcellular distribution of swine vesicular disease virus proteins and alterations induced in infected cells: a comparative study with foot-and-mouth disease virus and vesicular stomatitis virus. Virology 374:432-443.
39. Meijering, E., et al. 2004. Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. Cytometry A 58:167-176. (Pubitemid 38509178)
40. Novella, I. S., et al. 1996. Large-population passages of vesicular stomatitis virus in interferon-treated cells select variants of only limited resistance. J. Virol. 70:6414-6417.
41. Nunez, J. I., et al. 1998. A RT-PCR assay for the differential diagnosis of vesicular viral diseases of swine. J. Virol. Methods 72:227-235.
42. Ohdo, S., S. Nakano, and N. Ogawa. 1988. Chronopharmacological study of sodium valproate in mice: dose-concentration-response relationship. Jpn. J. Pharmacol. 47:11-19.
43. Ono, A., S. D. Ablan, S. J. Lockett, K. Nagashima, and E. O. Freed. 2004. Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc. Natl. Acad. Sci. U. S. A. 101:14889-14894.
44. Pereira, A. A., and I. M. Jacobson. 2009. New and experimental therapies for HCV. Nat. Rev. Gastroenterol. Hepatol. 6:403-411.
45. Pollack, G. M., and D. D. Shen. 1985. A timed intravenous pentylenetetrazol infusion seizure model for quantitating the anticonvulsant effect of valproic acid in the rat. J. Pharmacol. Methods 13:135-146.
46. Rodriguez, L. L. 2002. Emergence and re-emergence of vesicular stomatitis in the United States. Virus Res. 85:211-219.
47. Rosas, M. F., et al. 2008. Susceptibility to viral infection is enhanced by stable expression of 3A or 3AB proteins from foot-and-mouth disease virus. Virology 380:34-45.
48. Shaltiel, G., et al. 2004. Valproate decreases inositol biosynthesis. Biol. Psychiatry 56:868-874.
49. Soares, M. M., S. W. King, and P. E. Thorpe. 2008. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat. Med. 14:1357-1362.
50. Sobrino, F., M. Davila, J. Ortin, and E. Domingo. 1983. Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. Virology 128:310-318.
51. Strober, W. 2001. Trypan blue exclusion test of cell viability. Curr. Protoc. Immunol. Appendix 3:Appendix 3B.
52. Terbach, N., and R. S. Williams. 2009. Structure-function studies for the panacea, valproic acid. Biochem. Soc. Trans. 37:1126-1132.
53. Tokuoka, S. M., A. Saiardi, and S. J. Nurrish. 2008. The mood stabilizer valproate inhibits both inositol- and diacylglycerol-signaling pathways in Caenorhabditis elegans. Mol. Biol. Cell 19:2241-2250.
54. Venkataramani, V., et al. 2010. Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the Alzheimer amyloid precursor protein. J. Biol. Chem. 285:10678-10689.
55. Ventoso, I., et al. 2006. Translational resistance of late alphavirus mRNA to eIF2 phosphorylation: a strategy to overcome the antiviral effect of protein kinase PKR. Genes Dev. 20:87-100.
56. Welsch, S., et al. 2009. Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe 5:365-375.
57. Wittenburg, L. A., L. Bisson, B. J. Rose, C. Korch, and D. H. Thamm. 2010. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother. Pharmacol. doi:10.1007/s00280-010-1287-z.
58. Wolf, M. C., et al. 2010. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl. Acad. Sci. U. S. A. 107:3157-3162.
59. Xu, X., et al. 2007. Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid. Eukaryot. Cell 6:899-906.
60. Zajac, B. A., and K. Hummeler. 1970. Morphogenesis of the nucleoprotein of vesicular stomatitis virus. J. Virol. 6:243-252.
61. Zhou, J., A. R. Snyder, and P. M. Lieberman. 2009. Epstein-Barr virus episome stability is coupled to a delay in replication timing. J. Virol. 83:2154-2162.